We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Rediscovering risk

26 October 2006 By Robert Cyran

The two UK pharma giants have seen their share prices crushed by the failures of highrisk drugs under development. Pharmas look vulnerable to even small disappointments. Sector multiples have expanded, but growth in global drug sales continues to fall.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)